Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
43 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Axillary Hyperhidrosis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Axillary Hyperhidrosis - Pipeline Review, H2 2014', provides an overview of the Axillary Hyperhidrosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Axillary Hyperhidrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Axillary Hyperhidrosis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Axillary Hyperhidrosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Axillary Hyperhidrosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Axillary Hyperhidrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Axillary Hyperhidrosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Axillary Hyperhidrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Axillary Hyperhidrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Axillary Hyperhidrosis Overview 6 Therapeutics Development 7 Pipeline Products for Axillary Hyperhidrosis - Overview 7 Pipeline Products for Axillary Hyperhidrosis - Comparative Analysis 8 Axillary Hyperhidrosis - Therapeutics under Development by Companies 9 Axillary Hyperhidrosis - Pipeline Products Glance 10 Clinical Stage Products 10 Axillary Hyperhidrosis - Products under Development by Companies 11 Axillary Hyperhidrosis - Companies Involved in Therapeutics Development 12 GlaxoSmithKline plc 12 Actavis plc 13 Revance Therapeutics, Inc. 14 TheraVida, Inc. 15 Brickell Biotech, Inc. 16 Dermira Inc. 17 Axillary Hyperhidrosis - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Target 19 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 27 oxybutynin hydrochloride - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 RT-001 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 solifenacin - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 ANT-1403 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 onabotulinumtoxin A - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 DRM-04 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 umeclidinium bromide - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 BBI-4000 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Axillary Hyperhidrosis - Recent Pipeline Updates 37 Axillary Hyperhidrosis - Dormant Projects 40 Axillary Hyperhidrosis - Product Development Milestones 41 Featured News & Press Releases 41 Mar 19, 2014: Anterios Announces Development Of Next Generation Injectable Botulinum Product 41 Appendix 42 Methodology 42 Coverage 42 Secondary Research 42 Primary Research 42 Expert Panel Validation 42 Contact Us 43 Disclaimer 43
List of Tables Number of Products under Development for Axillary Hyperhidrosis, H2 2014 7 Number of Products under Development for Axillary Hyperhidrosis - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Comparative Analysis by Clinical Stage Development, H2 2014 10 Products under Development by Companies, H2 2014 11 Axillary Hyperhidrosis - Pipeline by GlaxoSmithKline plc, H2 2014 12 Axillary Hyperhidrosis - Pipeline by Actavis plc, H2 2014 13 Axillary Hyperhidrosis - Pipeline by Revance Therapeutics, Inc., H2 2014 14 Axillary Hyperhidrosis - Pipeline by TheraVida, Inc., H2 2014 15 Axillary Hyperhidrosis - Pipeline by Brickell Biotech, Inc., H2 2014 16 Axillary Hyperhidrosis - Pipeline by Dermira Inc., H2 2014 17 Assessment by Monotherapy Products, H2 2014 18 Number of Products by Stage and Target, H2 2014 20 Number of Products by Stage and Mechanism of Action, H2 2014 22 Number of Products by Stage and Route of Administration, H2 2014 24 Number of Products by Stage and Molecule Type, H2 2014 26 Axillary Hyperhidrosis Therapeutics - Recent Pipeline Updates, H2 2014 37 Axillary Hyperhidrosis - Dormant Projects, H2 2014 40
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.